Cancer Chemotherapy and Biotherapy

Principles and Practice
Fifth
ISBN: 978-1-60547-431-1
Verlag: Lippincott Williams and Wilkins

Buch, Englisch, 848 Seiten, Format (B × H): 213 mm x 276 mm, Gewicht: 2177 g

Updated to include the newest drugs and those currently in development, Cancer Chemotherapy and Biotherapy, Fifth Edition is a comprehensive reference on the preclinical and clinical pharmacology of anticancer agents. Organized by drug class, the book provides the latest information on all drugs and biological agents—their mechanisms of action, interactions with other agents, toxicities, side effects, and mechanisms of resistance. Chapters emphasize pharmacology and mechanisms of action at the molecular and cellular levels, followed by clinical activity and toxicity, both acute and delayed. The authors explain the rationale for use of drugs in specific schedules and combinations and offer guidelines for dose adjustment in particular situations.
This edition's introduction includes timely information on general strategies for drug usage, the science of drug discovery and development, economic and regulatory aspects of cancer drug development, and principles of pharmacokinetics. Eight new chapters have been added and more than twenty have been significantly revised.
A companion website includes the fully searchable text and an image bank.

Autoren/Hrsg.

Chabner, Bruce A.

Longo, Dan L.

Fachgebiete

• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizinische Fachgebiete Pharmakotherapie, Psychopharmakotherapie
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizinische Fachgebiete Pharmakologie, Toxikologie
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizinische Fachgebiete Bildgebende Verfahren, Nuklearmedizin, Strahlentherapie Nuklearmedizin, PET, Radiotherapie

Inhaltsverzeichnis

Section 1: BASIC PRINCIPLES OF CANCER TREATMENT
1: Clinical Strategies for Cancer Treatment: The Role of Drugs

Bruce Chabner
2: Target Identification and Drug Discovery

Ed Sausville
3: Clinical Drug Development and Approval for Marketing

Thomas Roberts
4: Principles of Pharmacokinetics

Jerry Collins
5: Special Aspects of Brain Tumor Chemotherapy

Jeffrey Supko & Tracy Batchelor
6: Pharmacogenetics

Howard McLeod
7: Barriers to Drug Delivery

Brendan Curti
Section 2: CYTOTOXIC AGENTS
8: Antifolates

Carmen Allegra & Bruce Chabner
9: Fluoro-pyrimidines

David Ryan, Bruce Chabner & Ray Wadlow
10: Cytidine Analogues

David Ryan & Bruce Chabner
11: Purine Analogues

Ken Hande
12: Hydroxyurea

Bruce Chabner
13: Antimitotic Drugs

Ross Donehower
14: Alkylating Agents (Including Methylating Agents)

Stan Gerson & Henry Friedman
15: Platinum Analogues

Ed Reed
16: Antitumor Antibiotics (Including Bleomycin)

Bruce Chabner
17: Topoisomerase I Inhibitors

Alex Spaareboom & William Zamboni
18: Topoisomerase II Inhibitors: Anthracyclines

Jim Doroshow
19: Topoisomerase II Inhibitors: Etoposide, Teniposide

George Hartman & Yves Pommier
20: L-Asparaginase

Bruce Chabner & Alison Friedmann
Section 3: MOLECULARLY TARGETED THERAPIES
21: Proteosome Inhibitors

Orhan Sezar
22: HDAC Inhibitors

Susan Bates
23: Differentiating Agents (Retinoids)

Bruce Chabner
24: Arsenic Trioxide

Bruce Chabner
25: Monoclonal Antibodies: Discovery & Development

David Scheinberg
26: Anti-angiogenic Agents (Including MonAB)

William Gradishar & Kari Wisinski
27: Anti-EGFR Therapies (Including MonAB)

Lecia Sequist & Joel Neal
28: Anti-her 2 Therapies

Eric Winer
29: Intracellular Signal Inhibitors (bcr-abl)

Bruce Chabner & Jeffrey Barnes
30: Signal Transduction Inhibitors in Development

Jeff Clark
31: Inhibitors of the PI3k Pathway & Mitotic Kinase

Percy Ivy
Section 4: IMMUNOLOGIC AGENTS
32: Interferon and Cytokines

David McDermott
33: Vaccines

Robert G. Fenton
34: Adoptive Cellular Therapies

Cassian Yee
35: Immuno-modulatory Drugs (IMIDS, Anti-CTLA4)

Paul Richardson et al.
Section 5: HORMONAL THERAPY
36: Hormonal Therapy of Breast Cancer

Beverly Moy & Paul Goss
37: GNRH Agonists and Anti-Androgens

Richard Lee
Section 6: SUPPORTIVE CARE
38: Pain Management in Cancer Patients

Paul Glare
39: Colony Stimulating Factors

Gary Lyman
40: Anti-nausea Medications

Ian Olver
41: Bone Loss Modulators

Matthew Smith
42: Intravenous Access and Catheter Management

Rachel Rosovsky
Section 7: SURVIVORSHIP
43: Monitoring for Late Side Effects of Chemotherapy

Richard Schilsky, Charles Erlichman & Brian Costello